[{"from": "human", "value": "Provide a description of this molecule. [C][C][Branch2][Branch2][Branch2][C][C][C][=Branch2][Ring1][C][=C][Branch1][Ring2][C][Ring1][=Branch1][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][Cl][C][N][C][C][N][Branch1][Branch1][C][C][Ring1][=Branch1][C][=C][C][=Branch2][Ring2][S][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][C][=Branch1][C][=O][N][S][=Branch1][C][=O][=Branch1][C][=O][C][=C][C][=Branch2][Ring1][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][N][C][C][C][C][O][C][C][Ring1][=Branch1][N+1][=Branch1][C][=O][O-1][O][C][=C][N][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][C][=C][N][Ring1][=Branch1][C]"}, {"from": "gpt", "value": "The molecule is an oral selective BCL-2 inhibitor and antineoplastic agent used in the therapy of refractory chronic lymphocytic leukemia (CLL). Venetoclax is associated with a low rate of transient serum enzyme elevations during therapy, but has not been implicated in cases of clinically apparent acute liver injury with jaundice. Venetoclax has potent immunosuppressive activity and may be capable of causing reactivation of hepatitis B."}]